|
CBLB expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.39780426017455E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.93400850889702E-13 |
| Normal-vs-Stage2 |
3.913800E-02 |
| Normal-vs-Stage3 |
1.52510004625128E-10 |
| Normal-vs-Stage4 |
1.10280007348251E-10 |
| Stage1-vs-Stage2 |
1.796350E-01 |
| Stage1-vs-Stage3 |
2.776200E-01 |
| Stage1-vs-Stage4 |
4.010600E-01 |
| Stage2-vs-Stage3 |
8.752000E-02 |
| Stage2-vs-Stage4 |
1.075550E-01 |
| Stage3-vs-Stage4 |
8.193600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.99200722162641E-16 |
| Normal-vs-AfricanAmerican |
3.65440000482664E-08 |
| Normal-vs-Asian |
1.16419995865868E-09 |
| Caucasian-vs-AfricanAmerican |
5.075600E-01 |
| Caucasian-vs-Asian |
9.778000E-01 |
| AfricanAmerican-vs-Asian |
5.009200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.04130004618952E-09 |
| Normal-vs-Female |
1.36780031745332E-10 |
| Male-vs-Female |
6.846800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.38398231447945E-12 |
| Normal-vs-Age(41-60Yrs) |
2.44249065417534E-15 |
| Normal-vs-Age(61-80Yrs) |
5.92229999999416E-05 |
| Normal-vs-Age(81-100Yrs) |
1.822940E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.950000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.700800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.176600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.020600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.335200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.891400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.805940E-02 |
| Classical-VS-Follicular |
3.58420000000637E-05 |
| Classical-VS-Other |
8.013400E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
3.54820000048051E-07 |
| Tall-VS-Other |
4.156000E-01 |
| Tall-VS-Normal |
1.92068583260152E-14 |
| Follicular-VS-Other |
2.386000E-01 |
| Follicular-VS-Normal |
1.045440E-01 |
| Other-VS-Normal |
3.024800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.41839999745486E-08 |
| Normal-vs-N1 |
2.3759882950003E-12 |
| N0-vs-N1 |
1.258370E-02 |
|
|
